Generic diabetes combo drug put to the test in healthy volunteers

NCT ID NCT07633015

Completed Knowledge-focused Sponsor: ADIUM Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checked whether a generic version of the diabetes drug empagliflozin/metformin is absorbed into the body the same way as the brand-name drug Synjardy. 42 healthy adults took a single dose of each tablet under fed conditions. The goal was to see if the two versions are bioequivalent, meaning they work equally well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin and Metformin combination tablet
What this could lead to: If successful, this could confirm that the generic version is equivalent to the brand-name drug, potentially offering a lower-cost option for patients.
What could go wrong: This is a small, early-stage bioequivalence study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS

Contacts and locations

Locations

Axis Clinicals Latina, S.A. de C.V.

Mexico City, Mexico City, 07870, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.